Karnezis, Tom T <br/><br/>
Efficacy of intranasal Bevacizumab (Avastin) treatment in patients with hereditary hemorrhagic telangiectasia-associated epistaxis.  [electronic resource] 

 -  The Laryngoscope  Mar 2011 
 - 636-8 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1531-4995 
<br/><br/><label>Standard No.: </label>10.1002/lary.21415  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Intranasal<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Angiogenesis Inhibitors--administration & dosage<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Humanized<br/>Bevacizumab<br/>Combined Modality Therapy<br/>Dose-Response Relationship, Drug<br/>Epistaxis--drug therapy<br/>Female<br/>Humans<br/>Injections<br/>Laser Coagulation<br/>Lasers, Solid-State--therapeutic use<br/>Male<br/>Middle Aged<br/>Nasal Mucosa--drug effects<br/>Nasal Sprays<br/>Recurrence<br/>Retrospective Studies<br/>Telangiectasia, Hereditary Hemorrhagic--drug therapy<br/>Young Adult